Jon Napitupulu

Galapagos will wind down its cell therapy business following a strategic review and reported a nine‑month 2025 net loss...

Aquestive Therapeutics is steering its sublingual epinephrine candidate, Anaphylm, toward a potential U.S. launch in the first quarter of...

Revolution Medicines advanced its RAS(ON) portfolio with multiple late-stage moves: global enrollment is winding down for Rasolute 302, the...

ADMA Biologics posted third-quarter 2025 revenue of $134.2 million, up 12% year over year, with GAAP net income of...

Cytek Biosciences posted third-quarter 2025 revenue of $52.3 million, up 2% year over year, and expanded its installed base...

Kymera Therapeutics has completed enrollment and dosing in its Phase 1b BROADEN study of KT-621, a first-in-class, once-daily oral...

Avicanna has reshaped its board, accepting the resignation of director Paul Fornazzari and appointing capital-markets veteran Michael Kott effective...

Organogenesis has begun a rolling biologics license application with the FDA for Renu, a cryopreserved amniotic suspension allograft for...

Avicanna has announced a board transition, with Paul Fornazzari stepping down and Michael Kott joining as a director on...

Amneal Pharmaceuticals and Mabxience have secured FDA approvals for Boncresa (denosumab-mobz), a biosimilar to Prolia, and Oziltus (denosumab-mobz), a...